查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1250776

到 2028 年阿片类药物使用障碍 (OUD) 市场预测——按药物类别、分销渠道、给药途径、年龄组和地区进行的全球分析

Opioid Use Disorder Market Forecasts to 2028 - Global Analysis By Drug Class, Distribution Channel, Route of Administration, Age group, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球阿片类药物使用障碍 (OUD) 市场预计将在 2022 年占 31.7 亿美元，到 2028 年将达到 67.9 亿美元。预计将以 13.5 的复合年增长率增长预测期内的百分比。

阿片类药物是一类可以放鬆肌肉、缓解疼痛，还可以缓解压力的药物。 为了治疗中度至重度疼痛，医生通常会开一些药物，例如氢可酮、羟考酮、可待因、芬太尼、美沙酮、吗啡和其他处方阿片类药物。 它被认为是一种大脑疾病，因为它涉及与动机、压力、自我控制和决策相关的大脑迴路的功能变化，这些变化在停止吸毒后很长时间内仍会持续存在。

市场动态：

驱动程序

对支持政府和非政府组织扩张的兴趣增加

政府和非政府组织越来越多地参与提高对阿片类药物过量及其相关后果的认识，这也推动了该企业的扩张。 随着阿片类药物成瘾的激增，一些团体正在加紧努力解决这个问题。 许多国家正在加紧努力帮助患者并减少阿片类药物依赖的影响。 例如，卫生与公共服务部 (HHS) 已宣布资助药物滥用治疗和预防计划，以改善阿片类药物使用障碍的药物辅助治疗的可及性并遏制处方药滥用。 预计类似计划将鼓励更多有阿片类药物相关问题的人寻求治疗。

抑製剂：

OUD药物的副作用

由于用于治疗阿片类药物成瘾的药物的不利影响，市场预计在预测期内将面临挑战。 这些药物经常引起肌肉疼痛、噁心、呕吐、腹泻、骨骼和关节疼痛、呼吸系统问题、膀胱疼痛、便秘和腹部绞痛。 此外，在药物反应的极端情况下，人们可能会出现抑郁和其他心理问题。 由于这些药物存在的危险，美国食品和药物管理局已经发出警告，这对这类药物产生了负面影响，并导致减少用于此类治疗的药物的使用。

机会

越来越关注丁丙诺啡贴剂

最近，市场上观察到对丁丙诺啡贴剂治疗的需求不断增加。 这些贴剂被认为是治疗阿片类药物使用障碍的有效药物。 与传统的自我给药相比，透皮贴剂具有许多优势，包括更简单的药物输送机制和更少的疼痛。 对于需要 24/7 全天候阿片类药物治疗的阿片类药物使用障碍患者，透皮贴剂也可能是一种有效的替代方案。 此外，在预测期内，越来越多的新患者预计将促进全球阿片类药物使用障碍 (OUD) 市场的增长。

威胁

效应器戒断综合征

戒断综合征是在停止反復接触药物刺激后发展起来的，与依赖性有关。 应警告患者在不先减少剂量的情况下不要停止长期使用阿片类药物。 作为物质使用障碍的一个子类，成瘾可能会出现身体、心理或两者兼而有之的症状和体征。 无论使用何种类型的阿片类药物，戒断症状通常在依赖开始时开始出现。 阿片类药物使用障碍的主要问题是戒断症状。 与美沙酮相比，海洛因戒断症状最早可能在最后一次服药后 5 小时开始出现。 当戒断症状持续数天至数週时，称为长期戒断综合征。

COVID-19 的影响

冠状病毒大流行对製药行业产生了一系列积极和消极影响，具体取决于需求。 对医院和诊所等医疗机构的就诊人数减少对某些药物的需求产生了不利影响。 此外，一些政府已在全国范围内发出严重警报，以努力减少感染冠状病毒的人数。 结果，医院之间的患者流动极差。 此外，医疗程序不必要的取消或延误对市场增长产生了负面影响。 然而，在大流行期间，包括 Indivior PLC 在内的在阿片类药物使用障碍市场运营的知名公司的产品收入全面下滑。 由于与 COVID-19 相关的中断，例如锁定和运输问题，销售额也直线下降。 因此，预计阿片类药物使用障碍市场将消退。

丁丙诺啡细分市场预计在预测期内将成为最大的细分市场

估计丁丙诺啡细分市场将实现有利增长。 丁丙诺啡/诺洛酮舌下片、丁丙诺啡舌下片、商品名 Suboxone 最常被推荐用于治疗 OUD。 由于其卓越的临床表现，Suboxonefilm 已成为 OUD 市场上医生最常开的处方药。 该药物的高接受度可能归因于许多变量，包括高处方覆盖率、高成瘾控制、低滥用可能性和最小的副作用。你可以

在预测期内，肠外药物领域有望呈现最高复合年增长率

由于各种剂量的 OUD 疗法以肠胃外给药形式的可用性，在预测期内，肠胃外给药部分预计将以最快的复合年增长率增长。 因此，这种给药方法继续主导着全球市场。

市场份额最高的地区

由于公众对 OUD 的认识不断提高，预计亚太地区在预测期内将占据最大的市场份额。 此外，该地区的高患者人数和不断增长的医疗保健支出预计将推动该地区的市场增长。

复合年增长率最高的地区：

预计北美在预测期内的复合年增长率最高。 北美市场份额最高的主要驱动因素之一是美国和加拿大的阿片类药物流行病，许多政府举措都已到位。 例如，美国政府发起了一场打击阿片类药物成瘾的公众意识运动。 较新的药物，如 Braeburn 的 CAM-2038-每月定期注射的附加丁丙诺啡皮下製剂，预计也将在整个预测年度进入美国市场。

主要发展：

2022 年 3 月，Collegium Pharmaceutical, Inc. 宣布已完成对 BioDelivery Sciences International Inc. 的收购。

2020 年 6 月，Titan Pharmaceuticals, Inc. 与 Indegene 建立合作伙伴关係，在美国建立多渠道数字营销计划，以进一步增强其向阿片类药物成瘾者提供 Probuphine 植入物 2016 的能力。.

2021 年 2 月，Orexo AB 宣布与 ApexB.io 和 Magellan Rx Management 合作，进一步研究 Modia 的使用。 该产品是专为患有阿片类药物使用障碍的患者设计的数字疗法。

2020 年 12 月，Orexo AB 与 Accord Healthcare 就 ZUBSOLV 和纳洛酮舌下片在欧洲的商业化签订了独家协议。

2019 年 2 月，雷迪博士实验室宣布在一项专利诉讼中获得有利判决后重新推出丁丙诺啡和纳洛酮舌下薄膜。

这份报告提供了什么

  • 区域和国家级细分市场的市场份额评估
  • 向新进入者提出战略建议
  • 2020、2021、2022、2025 和 2028 年的综合市场数据
  • 市场驱动因素（市场趋势、制约因素、机遇、威胁、挑战、投资机会/建议等）
  • 根据市场预测在关键业务领域提出战略建议
  • 竞争格局和趋势
  • 公司简介，包括详细的战略、财务状况和近期发展
  • 供应链趋势反映了最新的技术进步。

提供免费定制

购买此报告的客户将免费获得以下定制之一。

  • 公司简介
    • 对其他市场参与者（最多 3 个）进行全面分析
    • 主要参与者的 SWOT 分析（最多 3 人）
  • 区域细分
    • 应客户要求提供主要国家/地区的市场估算、预测和復合年增长率（注意：通过可行性检查）
  • 竞争基准
    • 根据产品组合、地域分布和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

  • 概览
  • 利益相关者
  • 调查范围
  • 调查方法
    • 数据挖掘
    • 数据分析
    • 数据验证
    • 研究方法
  • 调查来源
    • 主要研究信息来源
    • 二手研究资源
    • 假设

第三章市场趋势分析

  • 司机
  • 约束因素
  • 机会
  • 威胁
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第 5 章全球阿片类药物使用障碍 (OUD) 市场：按药物类别分类

  • 美沙酮
  • 纳曲酮
  • 丁丙诺啡
    • 布纳维尔
    • 子加载
    • 萨博森
    • Zubsolve

第 6 章。全球阿片类药物使用障碍 (OUD) 市场：按分销渠道

  • 零售药店和商店
  • 医院药房
  • 在线药店

第 7 章。全球阿片类药物使用障碍 (OUD) 市场：按给药途径

  • 肠外
  • 口语

第 8 章。全球阿片类药物使用障碍 (OUD) 市场：按年龄组分类

  • 19-39岁
  • 40-59
  • 60 岁以上

第 9 章。全球阿片类药物使用障碍 (OUD) 市场：按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东地区

第10章主要发展

  • 合同、伙伴关係、协作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • Alkermes
  • Titan Pharmaceuticals, Inc
  • Hikma Pharmaceuticals PLC
  • Indivior PLC
  • Mallinckrodt Pharmaceuticals
  • Camurus
  • Orexo AB
  • Viatris Inc
  • BioDelivery Sciences International Inc.
  • Teva Pharmaceuticals Usa, Inc
  • Mylan
  • Azanta
  • Braeburn
  • Chiesi Pharmaceuticals
  • DiaMo Narcotics
  • MaynePharma Group
  • Knight Therapeutics
  • Dr. Reddy's Laboratories
  • Collegium Pharmaceutical, Inc
  • Buvidal
Product Code: SMRC22653

According to Stratistics MRC, the Global Opioid Use Disorder (OUD) Market is accounted for $3.17 billion in 2022 and is expected to reach $6.79 billion by 2028 growing at a CAGR of 13.5% during the forecast period. Opioids are a class of medications that also relax muscles, lessen pain, and ease stress. To treat moderate to severe pain, doctors often prescribe drugs like hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other prescription opioids. It involves functional alterations to brain circuits associated to motivation, stress, self-control, and decision-making, and because those changes may persist for a long time after drug use has stopped, it is recognised as a brain condition.

Market Dynamics:

Driver:

Growing focus of government & non-government institutions to support expansion

The expansion of the business is being fuelled in part by the growing involvement of governmental and non-governmental organisations in raising awareness of opioid overdose and associated consequences. Several groups have expanded their efforts to combat the issue as a result of the sharp rise in the number of opioid addicts. In order to help patients and decrease the effects of opioid dependence, many countries have increased their efforts. For instance, Health and Human Services (HHS) announced financing for substance use treatment and prevention programmes in order to increase access to medication-assisted treatment for opioid use disorder and curb prescription drug abuse. It is predicted that similar programmes would motivate more people with opioid-related problems to seek treatment.

Restraint:

Adverse effects of OUD drugs

The market is expected to experience challenges throughout the forecast period due to the negative effects of the medications used to treat opioid addiction. These medications frequently cause muscle aches, nausea, vomiting, diarrhoea, bone or joint pain, respiratory problems, bladder pain, constipation, and cramping in the abdomen. In addition, in extreme instances of a medication reaction, the patient may also experience depression and other psychological issues. The U.S. FDA issued a warning due to the hazards involved with these medications, which has a negative effect on the drug class and decreases the use of medications for this type of treatment.

Opportunity:

Increasing consideration of buprenorphine patches

An increase in demand for buprenorphine patch treatments has lately been observed in the market. These patches are regarded as an effective medication for the treatment of opioid use disorders. Transdermal patches have a number of traditional, self-administered benefits, including an easier drug administration mechanism and less pain. Also, these transdermal patches might be a viable substitute for patients who need 24/7 opioid medication for opioid use disorder. Also, it is predicted that during the forecast period, a growing number of new patients will contribute to the growth of the global market for opioid use disorder (OUD).

Threat:

Effects withdrawal syndrome

Withdrawal syndrome, which develops when repeated exposure to a pharmaceutical stimulus is stopped, is linked to dependency. Patients should be warned not to stop using long-term opioids without first lowering their dosage. Substance use disorder's subcategory of dependency can show physical, psychological, or both signs and symptoms. Regardless of the type of opioid used, withdrawal symptoms usually begin around the time of dependence. The main issue with opioid use disorder is withdrawal. When compared to methadone, withdrawal from heroin might start as quickly as five hours following the last dose. Withdrawal symptoms that last for days or weeks are referred to as prolonged abstinence syndrome.

Covid-19 Impact

Due to demand, the coronavirus pandemic has a variety of effects on the pharmaceutical business, ranging from favourable to unfavourable. Because fewer people are visiting healthcare institutions like hospitals and clinics, there has been a detrimental effect on the demand for some medications. Furthermore, a handful of governments have implemented a rigorous nationwide lockdown in an effort to reduce the number of coronavirus cases. This has caused the flow of patients between hospital settings to drastically decrease. Moreover, the cancellation or delay of unnecessary medical treatments has had a detrimental effect on market expansion. However, throughout the pandemic, well-known companies operating in the market for opioid use disorders, including Indivior PLC, saw a general reduction in their product revenues. As a result of COVID-19-related disruptions including lockdowns, transportation problems, and others, sales have fallen down quickly. Thus, it is anticipated that the market for opioid use disorders will suffer a setback.

The buprenorphine segment is expected to be the largest during the forecast period

The buprenorphine segment is estimated to have a lucrative growth. The most frequently recommended medications for OUD are buprenorphine/naloxone sublingual pills, buprenorphine sublingual tablets, and brand-name Suboxone. Because to its outstanding clinical profile, Suboxone Film is the medication that doctors most frequently prescribe in the OUD market. The high acceptance of this medicine can be due to a number of variables, including its good formulary coverage, high efficacy in controlling addiction, low potential for abuse, and very minor adverse effects.

The parenteral segment is expected to have the highest CAGR during the forecast period

The parenteral segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the availability of several OUD medications in parenteral form and a range of dosages. As a result, this method of drug administration continues to rule the world market.

Region with highest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to increasing awareness amongst the general population regarding OUD. Additionally, the substantial patient population base and the increasing healthcare spending in the region are likely to favour the growth of the market in the region.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period. One of the major drivers behind North America's largest market share is the opioid epidemic that has ravaged the United States and Canada due to the governments are implementing a number of initiatives. For instance, the American government started a public awareness campaign to fight opioid addiction. Throughout the course of the projected year, new medications are also anticipated to enter the U.S. market, including Braeburn's CAM-2038-additional buprenorphine subcutaneous formulation for regular monthly injection.

Key Players in the market

Some of the key players profiled in the Opioid Use Disorder (OUD) Market include Alkermes, Titan Pharmaceuticals, Inc, Hikma Pharmaceuticals PLC, Indivior PLC, Mallinckrodt Pharmaceuticals, Camurus, Orexo AB, Viatris Inc, BioDelivery Sciences International Inc., Teva Pharmaceuticals Usa, Inc, Mylan, Azanta, Braeburn, Chiesi Pharmaceuticals, DiaMo Narcotics, MaynePharma Group, Knight Therapeutics, Dr. Reddy's Laboratories, Collegium Pharmaceutical, Inc and Buvidal.

Key Developments:

In March 2022, Collegium Pharmaceutical, Inc. announced that it had completed the acquisition of BioDelivery Sciences International Inc.

In June 2020, Titan Pharmaceuticals, Inc. entered into a partnership with Indegene to establish a multichannel digital marketing program throughout the U.S. and further increase their competence in providing Probuphine implant 2016 for opioid addiction patients.

In February 2021, Orexo AB announced its collaboration with ApexB.io and Magellan Rx Management to further research the use of Modia. This product is a digital therapeutic designed for patients with Opioid Use Disorder.

In December 2020, Orexo AB entered into an exclusive agreement with Accord Healthcare for the commercialization of ZUBSOLV and naloxone sublingual tablets in Europe.

In February 2019, Dr. Reddy's Laboratories announced the re-launch of its buprenorphine and naloxone sublingual film after the company received a favourable ruling in patent litigation.

Drug Classes Covered:

  • Methadone
  • Naltrexone
  • Buprenorphine

Distribution Channels Covered:

  • Retail Pharmacies & Stores
  • Hospitals Pharmacies
  • Online Pharmacies

Route of Administrations Covered:

  • Parenteral
  • Oral

Age groups Covered:

  • 19 to 39
  • 40 to 59
  • Age 60 and over

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Opioid Use Disorder (OUD) Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Methadone
  • 5.3 Naltrexone
  • 5.4 Buprenorphine
    • 5.4.1 Bunavail
    • 5.4.2 Sublocade
    • 5.4.3 Suboxone
    • 5.4.4 Zubsolv

6 Global Opioid Use Disorder (OUD) Market, By Distribution Channel

  • 6.1 Introduction
  • 6.2 Retail Pharmacies & Stores
  • 6.3 Hospitals Pharmacies
  • 6.4 Online Pharmacies

7 Global Opioid Use Disorder (OUD) Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Parenteral
  • 7.3 Oral

8 Global Opioid Use Disorder (OUD) Market, By Age group

  • 8.1 Introduction
  • 8.2 19 to 39
  • 8.3 40 to 59
  • 8.4 Age 60 and over

9 Global Opioid Use Disorder (OUD) Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Alkermes
  • 11.2 Titan Pharmaceuticals, Inc
  • 11.3 Hikma Pharmaceuticals PLC
  • 11.4 Indivior PLC
  • 11.5 Mallinckrodt Pharmaceuticals
  • 11.6 Camurus
  • 11.7 Orexo AB
  • 11.8 Viatris Inc
  • 11.9 BioDelivery Sciences International Inc.
  • 11.10 Teva Pharmaceuticals Usa, Inc
  • 11.11 Mylan
  • 11.12 Azanta
  • 11.13 Braeburn
  • 11.14 Chiesi Pharmaceuticals
  • 11.15 DiaMo Narcotics
  • 11.16 MaynePharma Group
  • 11.17 Knight Therapeutics
  • 11.18 Dr. Reddy's Laboratories
  • 11.19 Collegium Pharmaceutical, Inc
  • 11.20 Buvidal

List of Tables

  • Table 1 Global Opioid Use Disorder (OUD) Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 3 Global Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
  • Table 4 Global Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
  • Table 5 Global Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
  • Table 6 Global Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
  • Table 7 Global Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
  • Table 8 Global Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
  • Table 9 Global Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
  • Table 10 Global Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 11 Global Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
  • Table 12 Global Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 13 Global Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 14 Global Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 15 Global Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 16 Global Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
  • Table 17 Global Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
  • Table 18 Global Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
  • Table 19 Global Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
  • Table 20 Global Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
  • Table 21 North America Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
  • Table 22 North America Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 23 North America Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
  • Table 24 North America Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
  • Table 25 North America Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
  • Table 26 North America Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
  • Table 27 North America Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
  • Table 28 North America Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
  • Table 29 North America Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
  • Table 30 North America Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 31 North America Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
  • Table 32 North America Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 33 North America Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 34 North America Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 35 North America Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 36 North America Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
  • Table 37 North America Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
  • Table 38 North America Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
  • Table 39 North America Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
  • Table 40 North America Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
  • Table 41 Europe Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
  • Table 42 Europe Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 43 Europe Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
  • Table 44 Europe Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
  • Table 45 Europe Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
  • Table 46 Europe Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
  • Table 47 Europe Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
  • Table 48 Europe Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
  • Table 49 Europe Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
  • Table 50 Europe Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 51 Europe Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
  • Table 52 Europe Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 53 Europe Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 54 Europe Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 55 Europe Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 56 Europe Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
  • Table 57 Europe Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
  • Table 58 Europe Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
  • Table 59 Europe Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
  • Table 60 Europe Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
  • Table 61 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
  • Table 62 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 63 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
  • Table 64 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
  • Table 65 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
  • Table 66 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
  • Table 67 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
  • Table 68 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
  • Table 69 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
  • Table 70 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 71 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
  • Table 72 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 73 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 74 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 75 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 76 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
  • Table 77 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
  • Table 78 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
  • Table 79 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
  • Table 80 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
  • Table 81 South America Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
  • Table 82 South America Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 83 South America Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
  • Table 84 South America Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
  • Table 85 South America Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
  • Table 86 South America Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
  • Table 87 South America Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
  • Table 88 South America Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
  • Table 89 South America Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
  • Table 90 South America Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 91 South America Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
  • Table 92 South America Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 93 South America Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 94 South America Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 95 South America Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 96 South America Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
  • Table 97 South America Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
  • Table 98 South America Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
  • Table 99 South America Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
  • Table 100 South America Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
  • Table 101 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
  • Table 102 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 103 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
  • Table 104 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
  • Table 105 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
  • Table 106 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
  • Table 107 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
  • Table 108 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
  • Table 109 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
  • Table 110 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 111 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
  • Table 112 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 113 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 114 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 115 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 116 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
  • Table 117 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
  • Table 118 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
  • Table 119 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
  • Table 120 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)